Skip to main content
DLBCL: PFS but no OS benefit with polatuzumab-vedotin add-on
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
DLBCL: PFS but no OS benefit with polatuzumab-vedotin add-on
User login
Username
Password
Reset your password
Specialty
Lead
score
Hematology-Oncology
1
1
Concept
Lead
score
Diffuse Large Cell Lymphoma
0
1
Non-Hodgkin Lymphoma (NHL)
0
0.9
Biologic Therapy
0
0.56
Lymphoma
0
0.46
B-Cell Lymphoma
0
0.99
Antineoplastic Drug
0
0.4
Hodgkin Lymphoma
0
0.39
Indolent Lymphoma
0
0.39
Mediastinal Lymphoma
0
0.39
Monoclonal Antibody
0
0.36
Toxicology
0
0.36
Neutropenia
0
0.26
Cancer
0
0.18
Geriatrics
0
0.18
Adverse Effects
0
0.09
Anemia
0
0.09
Antibody Drug Conjugates
0
0.09
Blood
0
0.09
Concerns of Elderly
0
0.09
Hematology
0
0.09
New York
0
0.09
Patient Safety
0
0.09
Refractory
0
0.09
Remission
0
0.09
Tumor
0
0.09
Washington
0
0.09